AbbVie (NYSE:ABBV) Given New $265.00 Price Target at Cantor Fitzgerald
AbbVie (NYSE:ABBV – Get Free Report) had its target price boosted by analysts at Cantor Fitzgerald from $240.00 to $265.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has an “overweight†rating on the stock. Cantor Fitzgerald’s price objective points to a potential upside of 1.58% from the […]
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the briefHow this story developed
6 reports over 2 days-
thelincolnianonline.com Hudson Edge Investment Partners Inc. Has $7.12 Million Holdings in AbbVie Inc. $ABBV Neutral +14
-
simplywall.st Expanding RINVOQ And SKYRIZI Uses Might Change The Case For Investing In AbbVie (ABBV) Strong bullish +75
-
thelincolnianonline.com You're reading this AbbVie (NYSE:ABBV) Given New $265.00 Price Target at Cantor Fitzgerald Strong bullish +52
-
gurufocus.com ABBV Maintained by Cantor Fitzgerald -- Price Target Raised to $265 Strong bullish +67
Same story, other sources
How 1 other outlet framed itMore like this
